Elements of cancer immunity and the cancer-immune set point (Q39094764)

9 September 2017

Elements of cancer immunity and the cancer-immune set point (English)

1 reference

9 September 2017

Daniel S Chen

1

1 reference

PubMed ID

28102259

9 September 2017

Ira Mellman

series ordinal

2

1 reference

PubMed ID

28102259

9 September 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

9 September 2017

1 reference

9 September 2017

541

1 reference

9 September 2017

7637

1 reference

9 September 2017

321-330

1 reference

https://scigraph.springernature.com/pub.10.1038/nature21349

9 September 2017

0 references

cites work

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer immunotherapy comes of age

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Oncology meets immunology: the cancer-immunity cycle

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer/testis antigens, gametogenesis and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Therapeutic cancer vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Therapeutic vaccines for cancer: an overview of clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Exploiting the mutanome for tumor vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Neoantigen landscape dynamics during human melanoma-T cell interactions

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cause and consequences of genetic and epigenetic alterations in human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Individually distinct transplantation antigens of chemically induced mouse tumors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Adaptive immunity maintains occult cancer in an equilibrium state

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

IL-2: the first effective immunotherapy for human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

T cell exclusion, immune privilege, and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Innate and adaptive immune cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Innate immune recognition of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Basic principles of tumor-associated regulatory T cell biology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Molecular regulation of effector and memory T cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Genetic insights into common pathways and complex relationships among immune-mediated diseases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Cancer and the microbiota

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Influence of Statins on Influenza Vaccine Response in Elderly Individuals

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Widespread seasonal gene expression reveals annual differences in human immunity and physiology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21349

7 January 2021

Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28102259

12 December 2020

inferred from PubMed ID database lookup

Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28102259

12 December 2020

inferred from PubMed ID database lookup

Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28102259

12 December 2020

inferred from PubMed ID database lookup

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1200/JCO.2013.51.3572

Identifiers

DOI

10.1038/NATURE21349

1 reference

9 September 2017

1 reference

PubMed ID

28102259